Short Sellers Become More Focused on Big Pharma
The June 15 short interest data have been compared with the previous figures, and for the selected pharmaceutical stocks, short interest is mixed.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 261Short Sellers Get More Selective on Big Biotech
The short interest data are out for the June 15 settlement date, and overall, short interest in the selected biotech stocks was mixed.
Ritter Debuts Quietly in IPO Launch
Ritter Pharmaceuticals is the latest company to join in on the wave of initial public offerings.
Triple Leverage ETFs Launched in Biotech
For active traders and investors looking for juiced up returns in the hot biotech sector, ProShares has launched two triple leverage exchange traded funds in biotech.
Oral Testosterone Pill Could Make Lipocine Worth Substantially More
Lipocine may have a huge hit on its hands with the first swallowable oral testosterone treatment.
How MELA Plans to Buy XTRAC and VTRAC From PhotoMedex
PhotoMedex has announced that it will be selling its XTRAC and VTRAC psoriasis and vitiligo treatment businesses to MELA Sciences.
Benitec From Australia Files for US IPO: Gene Silencing and Gene Therapy
Benitec Biopharma, a clinical-stage biotechnology outfit, has filed for an initial public offering in the United States.
Will One of the Health Insurance Mergers Get a Cold Shoulder?
Merger talks within the health insurance sector are reaching a critical point, and it appears that there will be some major moves in the very near future.
CBO Cost Assumptions of Repealing Affordable Care Are Very Back-End Loaded
What is the public supposed to think when the Affordable Care Act is still under attack and the CBO says that repealing it would increase federal budget deficits by $137 billion over the 2016…
Healthways Trips Over Revised Guidance
Healthways announced that it will revise its guidance for 2015 due to lower than expected revenue from a single health plan contract and slower than expected business development for a couple projects.
3 Drivers Supporting BioMarin
BioMarin Pharmaceutical has three key drivers helping out its shares on Thursday: drug news, analyst support, record high Nasdaq.
Key Analyst Sees Solid Upside in Eli Lilly
Eli Lilly has made a big splash in the market over the past year. A key analyst sees this trend continuing despite some potential near-term headwinds.
Why This Analyst Sees Synergy Pharma Still Doubling Even After Huge Gains
A fresh report implies that Synergy shares, even after the monumental gain on Wednesday, could actually more than double.
What Allergan Is Looking to Add With Kythera
Allergan and Kythera Biopharmaceuticals announced that they have entered into a definitive agreement in which the former will acquire he latter in a cash and equity transaction valued at roughly $2.1 billion.
How Synergy Is Bringing the Ultimate Relief to Shareholders
If a drug is approved or passes a clinical trial, there can be a huge upside for the stock, like what Synergy Pharmaceuticals experienced Wednesday.